Enter your email address below to sign up for our Email Alerts, featuring developments and analysis of the industry and related Flowerkist information.

Competitive Landscape


The cosmetics category primarily consists of face makeup, eye makeup, lip products, nail products and cosmetics sets/kits and excludes beauty tools and accessories such as brushes and applicators.

Brand recognition, quality, performance, availability and price are some of the factors that impact consumers’ choices among competing products and brands. Advertising, promotion, merchandising, the pace and timing of new product introductions, line extensions and the quality of in-store demonstrations also have a significant impact on consumers’ buying decisions.

Cosmetics are broadly sold through food, drug and mass channels, as well as through department stores and direct and specialty channels. The cosmetics industry is relatively concentrated. A significant portion of cosmetics retail sales in the United States are generated by brands owned by L’Oreal S.A., The Estee Lauder Companies Inc., Revlon Inc., Coty Inc., and Shiseido Company, Limited. These large multinational companies own many brands across mass and prestige cosmetics. In addition to the traditional brands against which we compete, small independent companies continue to enter the market with new brands and customized product offerings.

Anti-Inflammatory Agents and Cosmetics

Anti-inflammatory agents are now commonly being incorporated into skin care products to improve skin tone and texture while reducing the appearance of aging.

Health & Wellness

The number of individuals suffering from chronic pain is rising at a substantial pace. Analysis of data from the 2012 National Health Interview Survey (NHIS) found that most American adults have experienced some level of pain, from brief to more lasting (chronic) pain, and from relatively minor to more severe pain.6F It found that an estimated 25.3 million adults (11.2 percent) experience chronic pain—that is, they had pain every day for the preceding 3 months. Nearly 40 million adults (17.6 percent) experience severe levels of pain. Those with severe pain are also likely to have worse health status.

Other Key Findings:

• An estimated 23.4 million adults (10.3%) experience a lot of pain
• An estimated 126 million adults (55.7%) reported some type of pain in the 3 months prior to the survey

Inflammation has long been a well-known symptom of many infectious diseases, but molecular and epidemiological research increasingly suggests that it is also intimately linked with a broad range of non-infectious diseases, perhaps even all of them. Although these insights might not lead to a unified theory of disease, the crucial role of inflammatory processes makes possible the development of a new generation of drugs to treat conditions including cancers, autoimmune disorders and infectious diseases.

There are scores of anti-inflammatory agents on the market, ranging from plain old aspirin to high-tech bioengineered molecules for treating asthma, rheumatoid arthritis, and multiple sclerosis. Long-term use of NSAIDs is a balancing act, because while it may keep the fires of inflammation burning low, it can also cause stomach bleeding and liver and kidney damage. The COX-2 inhibitors, especially rofecoxib (Vioxx), have been linked to increased heart attack risk.